- The company is testing 5 and 25 microgram doses in
an early stage study ; results are expected in July - Novavax’s insect-cell technology and the 5 microgram dose can be scaled up easily, R&D president
Gregory Glenn said, speaking at the second ISV Covid-19 Vaccines Virtual Congress - NVAX has $1.6 billion in funding from the U.S. government as well as backing
from CEPI - Company is on track for for 100m doses to U.S. by ...
Novavax Sees Advantage of Scale on Low-Dose Covid-19 Vaccine
July 21, 2020, 3:27 PM